3 completed, 2 active not recruiting, 2 withdrawn, 1 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Withdrawn 2, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 2, Withdrawn 1 |
Follow LFB-R603: new trials by email Literature Review of LFB-R603 trials Research Report on LFB-R603
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma Tazemetostat, Ublituximab, Umbralisib - Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2023-05-01 | 2023-05-31 | |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma Acalabrutinib, Ublituximab, Umbralisib - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 12 | 2021-03-26 | 2026-10-06 |
| Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Acalabrutinib, Umbralisib, Ublituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Jennifer R. Brown, MD, PhD | 29 | 2020-12-15 | 2026-02-25 |
| Study of TG-1801 in Subjects With B-Cell Lymphoma TG-1801, Ublituximab - B-Cell Lymphoma | Phase 1 | Completed | TG Therapeutics, Inc. | 50 | 2019-03-05 | 2024-04-08 |
| Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Ublituximab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 1 | Completed | Johns Hopkins University | 6 | 2016-01-01 | 2019-06-06 |
| LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia LFB-R603 - Chronic Lymphocytic Leukemia | Phase 1 | Completed | Laboratoire français de Fractionnement et de Biotechnologies | 33 | 2008-11-01 | 2012-04-30 |
Lymphoma, Follicular (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Mantle-Cell (2) · Myelitis, Transverse (1) · Neuromyelitis Optica (1) · Optic Neuritis (1) · Recurrence (1) · Waldenstrom Macroglobulinemia (1)
City of Hope Medical Center (2) · TG Therapeutics, Inc. (2) · Jennifer R. Brown, MD, PhD (1) · Johns Hopkins University (1) · Laboratoire français de Fractionnement et de Biotechnologies (1) · Yazeed Sawalha (1)
United States (4) · Australia (1) · France (1)
Alexey V Danilov (1) · Jennifer R Brown, MD, PhD (1) · Matthew Mei (1) · Michael Levy, MD, PhD (1) · Yazeed Sawalha, MD (1)
P30CA033572 (2)